Eupraxia Pharmaceuticals Inc (EPRX)
$2.65
+0.06
(+2.32%)▲
Market is closed - opens 7 PM, 07 Oct 2024
Performance
- $2.61$2.75$2.65
1.51%
Downside
Day's Volatility :5.09%
Upside
3.64%
- $2.39$3.50$2.65
9.81%
Downside
52 Weeks Volatility :31.71%
Upside
24.29%
Returns
| Period | Eupraxia Pharmaceuticals Inc | Index (Russel 2000) |
|---|---|---|
3 Months | 3.6% | 0.0% |
6 Months | -11.0% | 0.0% |
1 Year | -12.2% | 0.0% |
3 Years | -12.2% | -20.1% |
Highlights
Market Capitalization | 91.9M |
Book Value | $0.42 |
Earnings Per Share (EPS) | -0.93 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -98.68% |
Return On Equity TTM | -314.41% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -31.8M |
Diluted Eps TTM | -0.93 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
Buy
87%Buy
12%Hold
0
0%Sell
Based on 8 Wall street analysts offering stock ratings for Eupraxia Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
- Current
- 1M Ago
- 3M Ago
Buy
7
7
7
Hold
1
1
1
Sell
00
00
00
Technicals Summary
Sell
Neutral
Buy
Eupraxia Pharmaceuticals Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Eupraxia Pharmaceuticals Inc | 1.97% | -11.0% | -12.2% | -12.2% | -12.2% |
 Regeneron Pharmaceuticals, Inc. | -10.33% | 8.11% | 21.28% | 85.63% | 257.49% |
 Novo Nordisk A/s | -12.25% | -9.71% | 24.92% | 138.38% | 343.21% |
 Alnylam Pharmaceuticals, Inc. | 9.22% | 72.73% | 52.35% | 34.04% | 250.13% |
 Vertex Pharmaceuticals Incorporated | -3.09% | 12.2% | 25.77% | 150.7% | 163.62% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Eupraxia Pharmaceuticals Inc | NA | NA | NA | 0.0 | -3.14 | -0.99 | NA | 0.42 |
Regeneron Pharmaceuticals, Inc. | 27.55 | 27.55 | 1.42 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 38.7 | 38.7 | 1.75 | 3.41 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.49 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.55 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Eupraxia Pharmaceuticals Inc | Buy | $91.9M | -12.2% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $114.7B | 257.49% | 27.55 | 32.04% |
Novo Nordisk A/s | Buy | $518.0B | 343.21% | 38.7 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.9B | 250.13% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $119.3B | 163.62% | 32.84 | -4.74% |
Company Information
Organization | Eupraxia Pharmaceuticals Inc |
Employees | 29 |
CEO | Dr. James A. Helliwell FRCPC, M.D. |
Industry | Miscellaneous |
Discover More
Generation Income Properties Inc
$2.65
+2.32%
Touchstone Climate Transition Etf
$2.65
+2.32%
Atlas Lithium Corp
$2.65
+2.32%
Flexshares Quality Dividend
$2.65
+2.32%
Blackrock New York Muni Inc
$2.65
+2.32%
Timothy Plan International Etf
$2.65
+2.32%
Alger 35 Etf
$2.65
+2.32%
Aadi Bioscience Inc
$2.65
+2.32%
Goldman Sachs Access Inflati
$2.65
+2.32%